Literature DB >> 24603772

Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity.

Fujian Tan1, Ruizhi Yang, Xiaoxue Xu, Xiujie Chen, Yunfeng Wang, Hongzhe Ma, Xiangqiong Liu, Xin Wu, Yuelong Chen, Lei Liu, Xiaodong Jia.   

Abstract

Drug repositioning, also known as drug repurposing or reprofiling, is the process of finding new indications for established drugs. Because drug repositioning can reduce costs and enhance the efficiency of drug development, it is of paramount importance in medical research. Here, we present a systematic computational method to identify potential novel indications for a given drug. This method utilizes some prior knowledge such as 3D drug chemical structure information, drug-target interactions and gene semantic similarity information. Its prediction is based on another form of 'expression profile', which contains scores ranging from -1 to 1, reflecting the consensus response scores (CRSs) between each drug of 965 and 1560 proteins. The CRS integrates chemical structure similarity and gene semantic similarity information. We define the degree of similarity between two drugs as the absolute value of their correlation coefficients. Finally, we establish a drug similarity network (DSN) and obtain 33 modules of drugs with similar modes of action, determining their common indications. Using these modules, we predict new indications for 143 drugs and identify previously unknown indications for 42 drugs without ATC codes. This method overcomes the instability of gene expression profiling derived from experiments due to experimental conditions, and predicts indications for a new compound feasibly, requiring only the 3D structure of the compound. In addition, the high literature validation rate of 71.8% also suggests that our method has the potential to discover novel drug indications for existing drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24603772     DOI: 10.1039/c3mb70554d

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  16 in total

Review 1.  A survey of current trends in computational drug repositioning.

Authors:  Jiao Li; Si Zheng; Bin Chen; Atul J Butte; S Joshua Swamidass; Zhiyong Lu
Journal:  Brief Bioinform       Date:  2015-03-31       Impact factor: 11.622

Review 2.  Drug repurposing from the perspective of pharmaceutical companies.

Authors:  Y Cha; T Erez; I J Reynolds; D Kumar; J Ross; G Koytiger; R Kusko; B Zeskind; S Risso; E Kagan; S Papapetropoulos; I Grossman; D Laifenfeld
Journal:  Br J Pharmacol       Date:  2017-05-18       Impact factor: 8.739

3.  The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection and drug-drug interactions.

Authors:  Santiago Vilar; George Hripcsak
Journal:  Brief Bioinform       Date:  2017-07-01       Impact factor: 11.622

Review 4.  Artificial intelligence unifies knowledge and actions in drug repositioning.

Authors:  Zheng Yin; Stephen T C Wong
Journal:  Emerg Top Life Sci       Date:  2021-12-21

Review 5.  Signature-based approaches for informed drug repurposing: targeting CNS disorders.

Authors:  Rammohan Shukla; Nicholas D Henkel; Khaled Alganem; Abdul-Rizaq Hamoud; James Reigle; Rawan S Alnafisah; Hunter M Eby; Ali S Imami; Justin F Creeden; Scott A Miruzzi; Jaroslaw Meller; Robert E Mccullumsmith
Journal:  Neuropsychopharmacology       Date:  2020-06-30       Impact factor: 8.294

6.  A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network.

Authors:  Erkhembayar Jadamba; Miyoung Shin
Journal:  Biomed Res Int       Date:  2016-12-26       Impact factor: 3.411

Review 7.  A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions.

Authors:  Tamer N Jarada; Jon G Rokne; Reda Alhajj
Journal:  J Cheminform       Date:  2020-07-22       Impact factor: 5.514

8.  A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation.

Authors:  Yanqiong Zhang; Xia Mao; Wenjia Chen; Xiaodong Guo; Liangxiang Yu; Funeng Jiang; Xiaoyue Wang; Weijie Li; Qiuyan Guo; Taixian Li; Na Lin
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-10       Impact factor: 8.886

9.  Drug-repurposing identified the combination of Trolox C and Cytisine for the treatment of type 2 diabetes.

Authors:  Ling Jin; Jian Tu; Jianwei Jia; Wenbin An; Huanran Tan; Qinghua Cui; Zhixin Li
Journal:  J Transl Med       Date:  2014-05-31       Impact factor: 5.531

10.  Quantitative Identification of Compound-Dependent On-Modules and Differential Allosteric Modules From Homologous Ischemic Networks.

Authors:  B Li; J Liu; Y Y Zhang; P Q Wang; Y N Yu; R X Kang; H L Wu; X X Zhang; Z Wang; Y Y Wang
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.